Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||TP53 positive|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TP53 positive||Advanced Solid Tumor||predicted - sensitive||p28||Phase I||Actionable||In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360).||23449360|
|TP53 positive||ovarian cancer||predicted - sensitive||NU6027 + Temozolomide||Preclinical - Cell culture||Actionable||In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979).||21730979|
|TP53 positive||Advanced Solid Tumor||sensitive||Serdemetan||Phase I||Actionable||In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).||21831953|
|TP53 positive||breast cancer||sensitive||Serdemetan||Phase I||Actionable||In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).||21831953|
|TP53 positive||Advanced Solid Tumor||sensitive||MVAp53||Phase I||Actionable||In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03363867||Phase II||Atezolizumab + Bevacizumab + Cobimetinib||BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)||Recruiting||1|
|NCT01042535||Phase Ib/II||Ad.p53-DC vaccine + Indoximod||Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer||Completed||USA||0|
|NCT03560882||Phase I||Atorvastatin||A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies||Recruiting||USA||0|
|NCT02098343||Phase Ib/II||Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin||p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246||Completed||USA | FRA | ESP | DEU | BEL||3|
|NCT03063203||Phase II||Decitabine||Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia||Terminated||USA||0|